Investigated for treating COVID-19.
Tocilizumab-bavi (Tofidence) is biosimilar to Tocilizumab (Actemra).
Approved 09/29/2023
Tocilizumab-Aazg (Tyenne) is biosimilar to Tocilizumab (Actemra).
Approved 03/05/2024
Investigated for treating COVID-19.
Tocilizumab-bavi (Tofidence) is biosimilar to Tocilizumab (Actemra).
Approved 09/29/2023
Tocilizumab-Aazg (Tyenne) is biosimilar to Tocilizumab (Actemra).
Approved 03/05/2024
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of tocilizumab in the treatment of juvenile idiopathic arthritis in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 05/29/2024